Poland - Pharmaceutical products

For more information and to make a bid you will need to go to the third party website.

Details

Provided by Open Opps
Opportunity closing date
01 June 2022
Opportunity publication date
02 May 2022
Category
33600000: Ph
Value of contract
to be confirmed
Your guide to exporting
Report opportunity

Description

1) The subject matter of the contract is successive supply of medicinal products described in detail in Appendix 2A to SWZ (assortment-price form), which constitutes its integral part. (2) The Contracting Authority has defined in the description of the subject matter of the contract quality requirements referring to at least main elements that make up the subject matter of the contract - he demands delivery of medicinal products with precisely defined qualitative and quantitative composition - in this connection he makes use of the possibility indicated in art.246 item 2 of the Public Procurement Law. The Contracting Authority allows submitting partial offers: Total number of Parts in this procedure: 102.
The subject matter of the contract is successive supply of the medicinal product AMISULPRID, described in detail in Annex 2A to the SWZ. The Contracting Authority requires that the medicinal product in question has been authorized for marketing in Poland in accordance with the relevant provisions of the Pharmaceutical Law of September 6, 2001. Pharmaceutical Law (Dz.U. nr 126 poz. 1381 as amended). The subject of the contract is a successive delivery of a medicinal product AMITRIPTYLINE HYDROCHLORIDE, described in detail in Annex 2A to the SWZ. The Contracting Authority requires that the medicinal product in question has been authorized for marketing in Poland in accordance with the relevant provisions of the Act of 6 September 2001 on Pharmaceutical Law (Dz.U. of 2001, No. 649, item 1569, as amended). Pharmaceutical Law (Dz.U. nr 126 poz. 1381 as amended). The subject matter of the contract is successive supply of the medicinal product ARIPIPRAZOLE, described in detail in Annex 2A to the SWZ. The Ordering Party requires that the offered medicinal product has been authorized for marketing in the territory of Poland, in accordance with the relevant provisions of the Act of 6 September 2001 on Pharmaceutical Law (Dz.U. Pharmaceutical Law (Dz.U.), as amended). Pharmaceutical Law (Dz.U. nr 126 poz. 1381 as amended). The subject of the contract is the successive supply of the medicinal product BUPROPION, described in detail in Appendix No. 2A to the SWZ. The Purchaser requires that the offered medicinal product is admitted to marketing in Poland, in accordance with the provisions of the Act of 6 September 2001 on Pharmaceutical Law (Journal of Laws No 126, item 1381, as amended). Pharmaceutical Law (Dz.U. nr 126 poz. 1381 as amended). The subject of the order is a consecutive supply of a medicinal product CARIPRAZINE, described in detail in Appendix no. 2A to the SWZ. The Ordering Party requires that the medicinal product offered by the Ordering Party has been authorized for marketing in the territory of Poland, in accordance with the provisions of the Act of 6 September 2001 on Pharmaceutical Law (Journal of Laws No 126, item 1381, as amended). Pharmaceutical Law (Dz.U. nr 126 poz. 1381 as amended). The subject of the order is a consecutive supply of a medicinal product CHLORPROMAZINE HYDROCHLORIDE, described in detail in Annex 2A to the SWZ. The Ordering Party requires that the medicinal product in question has been authorized for marketing in Poland in accordance with the relevant provisions of the Act of 6 September 2001 on Pharmaceutical Law (Dz.U. [Official Journal of Laws], No. 6, item 1439, as amended). Pharmaceutical Law (Dz.U. nr 126 poz. 1381 as amended). The subject of the order is a consecutive supply of the medicinal product CHLOPROTHIXEN HYDROCHLORIDE, described in detail in Annex 2A to the SWZ. The Ordering Party requires that the offered medicinal product has been authorized for marketing on the territory of Poland, in accordance with the provisions of the Act of 6 September 2001 on Pharmaceutical Law (Dz.U. [Journal of Laws]). Pharmaceutical Law (Dz.U. nr 126 poz. 1381 as amended). The subject matter of the order is successive supply of the medicinal product CITALOPRAM, described in detail in Appendix No. 2A to SWZ (Terms of Reference). The Ordering Party requires that the offered medicinal product has been authorized for marketing in the territory of Poland, in accordance with the applicable provisions of the Act of 6 September 2001 on Pharmaceutical Law (Dz.U. No 126, item 1381 as amended). Pharmaceutical Law (Dz.U. nr 126 poz. 1381 as amended). The subject of the order is a consecutive supply of the medicinal product CLOMIPRAMINE HYDROCHLORIDE, described in detail in Annex 2A to the SWZ. The Ordering Party requires that the offered medicinal product has been authorized for marketing in the territory of Poland, in accordance with the relevant provisions of the Act of 6 September 2001 on Pharmaceutical Law (Dz. Pharmaceutical Law (Dz.U. nr 126 poz. 1381 as amended). The subject of the contract is a consecutive supply of CLOZAPINE, a medicinal product described in detail in Appendix No. 2A to the SWZ. The Purchaser requires that the offered medicinal product has been authorized for marketing in Poland, in accordance with the provisions of the Act of 6 September 2001 on Pharmaceutical Law (Journal of Laws No. 126, item 1381 as amended). Pharmaceutical Law (Dz.U. nr 126 poz. 1381 as amended). The subject of the contract is a consecutive supply of a medicinal product DOXEPIN, described in detail in Appendix No 2A to SWZ. The Purchaser requires that the offered medicinal product is authorized for marketing in the territory of Poland, in accordance with the provisions of the Act of 6 September 2001. Pharmaceutical Law (Dz.U. nr 126 poz. 1381 as amended). The subject of the contract is a consecutive supply of a medicinal product DULOXETINE, described in detail in Appendix no. 2A to SWZ. The Ordering Party requires that the offered medicinal product is authorized for marketing in the territory of Poland, in accordance with the provisions of the Act of 6 September 2001 on Pharmaceutical Law (Journal of Laws No. 126, item 1381, as amended). Pharmaceutical Law (Dz.U. nr 126 poz. 1381 as amended). The subject of the contract is a consecutive supply of a medicinal product ESCITALOPRAM, described in detail in Annex 2A to SWZ (Terms of Reference). The Contracting Authority requires that the medicinal product offered is authorized for marketing in the territory of Poland, in accordance with the provisions of the Act of 6 September 2001 on Pharmaceutical Law (Dz.U. Pharmaceutical Law). Pharmaceutical Law (Dz.U. nr 126 poz. 1381 as amended). The subject of the contract is a consecutive supply of the medicinal product FLUOXETINE, described in detail in Annex 2A to the SWZ. The Contracting Authority requires that the medicinal product offered is authorized for marketing in the territory of Poland, in accordance with the provisions of the Act of 6 September 2001 on Pharmaceutical Law (Journal of Laws No. 126, item 1381, as amended). Pharmaceutical Law (Dz.U. nr 126 poz. 1381 as amended). The subject of the contract is a consecutive supply of the medicinal product FLUPENTIXOL, described in detail in Annex 2A to the SWZ. The Ordering Party requires that the offered medicinal product has been authorized for marketing in the territory of Poland, in accordance with the relevant provisions of the Act of 6 September 2001 on Pharmaceutical Law (Dz.U. Pharmaceutical Law). Pharmaceutical Law (Dz.U. nr 126 poz. 1381 as amended). The subject of the contract is a consecutive supply of the medicinal product FLUPENTIXOL DECANOATE, described in detail in Annex 2A to the SWZ. The Ordering Party requires that the offered medicinal product has been authorized for marketing in the territory of Poland, in accordance with the applicable provisions of the Act of 6 September 2001 on Pharmaceutical Law (Dz.U. Pharmaceutical Law (Dz.U.), as amended). Pharmaceutical Law (Dz.U. nr 126 poz. 1381 as amended). The subject of the contract is a consecutive supply of a medicinal product FLUVOXAMINE MALEATE, described in detail in Annex 2A to the SWZ. The Ordering Party requires that the offered medicinal product is authorized for marketing in the territory of Poland, in accordance with the relevant provisions of the Act of 6 September 2001 on Pharmaceutical Law (Dz.U. Pharmaceutical Law, as amended). Pharmaceutical Law (Dz.U. nr 126 poz. 1381 as amended). The subject of the order is the successive supply of the medicinal product HALOPERIDOL, described in detail in Appendix No. 2A to SWZ. The Purchaser requires that the offered medicinal product has been authorized for marketing in the territory of Poland, in accordance with the relevant provisions of the Act of 6 September 2001 on Pharmaceutical Law (Journal of Laws of 2001, No. 114, item 1339 with amendments). Pharmaceutical Law (Dz.U. nr 126 poz. 1381 as amended). The subject of the contract is a consecutive supply of HYDROXYZINE medicinal product, described in detail in Annex 2A to the SWZ. The Client requires that the offered medicinal product is authorized for marketing in Poland, in accordance with the relevant provisions of the Act of 6 September 2001. Pharmaceutical Law (Dz.U. nr 126 poz. 1381 as amended). The subject of the order is successive supply of medicinal product LEVOMEPROMAZIN, described in details in Annex No 2A to SWZ. The Purchaser requires that the offered medicinal product is authorized for marketing in the territory of Poland, in accordance with the provisions of the Act of 6 September 2001 on Pharmaceutical Law (Journal of Laws Dz.U. 2001, as amended). Pharmaceutical Law (Dz.U. nr 126 poz. 1381 as amended). The subject matter of the order is successive supply of the medicinal product LITHIUM CARBONATE, described in detail in Appendix No. 2A to SWZ (Terms of Reference). The Ordering Party requires that the offered medicinal product has been authorized for marketing in the territory of Poland, in accordance with the relevant provisions of the Act of 6 September 2001 on Pharmaceutical Law (Dz.U. [Journal of Laws], no. 133, item 1339, as amended). Pharmaceutical Law (Dz.U. nr 126 poz. 1381 as amended). The subject of the contract is a successive supply of a medicinal product LURASIDONE, described in detail in Annex 2A to the SWZ. The Ordering Party requires that the offered medicinal product is authorized for marketing in the territory of Poland, in accordance with the provisions of the Act of 6 September 2001 on Pharmaceutical Law (Journal of Laws No. 126, item 1381, as amended). Pharmaceutical Law (Dz.U. nr 126 poz. 1381 as amended). The subject of the contract is a consecutive supply of a medicinal product MIANSERIN HYDROCHLORIDE, described in detail in the Attachment No 2A to SWZ. The Purchaser requires that the medicinal product in question has been authorized for marketing in Poland in accordance with the relevant provisions of the Act of 6 September 2001 on Pharmaceutical Law (Journal of Laws of 2001, No. 152, item 1439, as amended). Pharmaceutical Law (Dz.U. nr 126 poz. 1381 as amended). The subject of the contract is a successive supply of a medicinal product MIRTAZAPINE, described in detail in Annex 2A to the SWZ. The Ordering Party requires that the offered medicinal product has been authorized for marketing on the territory of Poland, in accordance with the provisions of the Act of 6 September 2001 on Pharmaceutical Law (Journal of Laws Dz.U. No. 126, item 1313, as amended). Pharmaceutical Law (Dz.U. nr 126 poz. 1381 as amended). The subject matter of the contract is the successive supply of the medicinal product MOCLOBEMID, described in detail in Appendix 2A to the SWZ. The Ordering Party requires that the offered medicinal product has been authorized for marketing in the territory of Poland, in accordance with the provisions of the Act of 6 September 2001 on Pharmaceutical Law (Dz.U. Pharmaceutical Law). Pharmaceutical Law (Dz.U. nr 126 poz. 1381 as amended). The subject of the contract is a consecutive supply of OLANZAPINE, described in detail in Annex 2A to the SWZ. The Purchaser requires that the offered medicinal product has been authorized for marketing in the territory of Poland, in accordance with the provisions of the Act of 6 September 2001 on Pharmaceutical Law (Journal of Laws No. 126, item 1381 as amended). Pharmaceutical Law (Dz.U. nr 126 poz. 1381 as amended). The subject of the contract is a consecutive supply of the medicinal product OPIPRAMOL DIHYDROCHLORIDE, described in detail in Annex 2A to the SWZ. The ordering party requires that the medicinal product in question has been authorized for marketing in Poland in accordance with the relevant provisions of the Act of 6 September 2001 on Pharmaceutical Law (Dz.U. Pharm. Pharmaceutical Law (Dz.U. nr 126 poz. 1381 as amended). The subject of the order is successive supply of the medicinal product PALIPERIDONE, described in detail in Appendix no. 2A to SWZ (Terms of Reference). The Ordering Party requires that the offered medicinal product has been authorized for marketing in the territory of Poland, in accordance with the applicable provisions of the Pharmaceutical Law of September 6th, 2001 (Dz.U. [Official Journal of Laws] No. 126, item 1313, as amended). Pharmaceutical Law (Dz.U. nr 126 poz. 1381 as amended). The subject of the order is a consecutive supply of therapeutic product PAROXETINE, described in detail in Annex 2A to the SWZ. The Purchaser requires that the medicinal product offered is authorized for marketing in Poland, in accordance with the relevant provisions of the Act of 6 September 2001. Pharmaceutical Law (Dz.U. nr 126 poz. 1381 as amended). The subject of the contract is a successive delivery of a medicinal product PERAZINE, described in details in Appendix No 2A to SWZ (SWZ). The Purchaser requires that the offered medicinal product has been admitted to marketing in Poland, according to the provisions of the Act of September 6th, 2001 on Pharmaceutical Law (Dz.U. No 126, item 1381 as amended). Pharmaceutical Law (Dz.U. nr 126 poz. 1381 as amended). The subject of the contract is a consecutive supply of PROMAZINE HYDROCHLORIDE, described in detail in Annex 2A to SWZ (SWZ). The Client requires that the offered medicinal product has been authorized for marketing in Poland, in accordance with the relevant provisions of the Act of 6 September 2001 on Pharmaceutical Law (Dz.U. Pharmaceutical Law (Dz.U.). Pharmaceutical Law (Dz.U. nr 126 poz. 1381 as amended). The subject of the contract is a consecutive supply of the medicinal product QUETIAPINE, described in detail in Appendix no 2A to SWZ. The Ordering Party requires that the medicinal product offered by the Ordering Party is admitted to marketing in Poland, in accordance with the provisions of the Pharmaceutical Law of September 6th, 2001 (Dz.U. No 126, item 1313 as amended). Pharmaceutical Law (Dz.U. nr 126 poz. 1381 as amended). The subject of the order is successive supply of the medicinal product RISPERIDONE, described in detail in Appendix No. 2A to the SWZ. The Ordering Party requires that the offered medicinal product has been admitted to marketing in Poland, in accordance with the provisions of the Act of 6 September 2001 on Pharmaceutical Law (Dz.U. [Journal of Laws], no. 126, item 1313, as amended). Pharmaceutical Law (Dz.U. nr 126 poz. 1381 as amended). The subject of the contract is a consecutive supply of SERTRALINE, a medicinal product described in detail in Appendix no. 2A to the SWZ. The Purchaser requires that the offered medicinal product is authorized for marketing in Poland, in accordance with the provisions of the Act of 6 September 2001. Pharmaceutical Law (Dz.U. nr 126 poz. 1381 as amended). The subject of the order is successive supply of the medicinal product SULPIRIDE, described in detail in Appendix 2A to SWZ (Terms of Reference). The Contracting Authority requires that the offered medicinal product has been authorized for marketing in Poland, in accordance with the relevant provisions of the Act of 6 September 2001 on Pharmaceutical Law (Dz.U. Pharm. Pharmaceutical Law (Dz.U. nr 126 poz. 1381 as amended). The subject of the order is a consecutive supply of a medicinal product TIANEPTINE SODIUM, described in detail in Appendix No 2A to the SWZ. The Purchaser requires that the offered medicinal product is authorized for marketing in Poland, in accordance with the relevant provisions of the Act of 6 September 2001. Pharmaceutical Law (Dz.U. nr 126 poz. 1381 as amended). The subject of the contract is a consecutive supply of a medicinal product TIAPRIDE, described in detail in Annex 2A to the SWZ. The Purchaser requires that the offered medicinal product is authorized for marketing in Poland, in accordance with the relevant provisions of the Act of 6 September 2001 on Pharmaceutical Law (Journal of Laws No. 126, item 1381, as amended). Pharmaceutical Law (Dz.U. nr 126 poz. 1381 as amended). The subject of the order is the successive supply of the medicinal product TRAZODONE HYDROCHLORIDE, described in detail in Appendix No. 2A to the SWZ. The Purchaser requires that the offered medicinal product is authorized for marketing in Poland, in accordance with the relevant provisions of the Act of 6 September 2001 on Pharmaceutical Law (Journal of Laws of 2001, No. 152, item 1439). Pharmaceutical Law (Dz.U. nr 126 poz. 1381 as amended). The subject matter of the contract is successive supply of the medicinal product VENLAFAXINE, described in detail in Appendix no. 2A to SWZ (Terms of Reference). The Ordering Party requires that the offered medicinal product has been authorized for marketing on the territory of Poland, in accordance with the provisions of the Act of September 6th, 2001 on Pharmaceutical Law (Dz.U. [Journal of Laws], No. 133, item 1339 as amended). Pharmaceutical Law (Dz.U. nr 126 poz. 1381 as amended). The subject matter of the contract is the successive supply of the medicinal product VORTIOXETINE, described in detail in Appendix 2A to the SWZ. The Purchaser requires that the offered medicinal product is authorized for marketing in the territory of Poland, in accordance with the provisions of the Act of 6 September 2001 on Pharmaceutical Law (Dz.U. Pharmaceutical Law). Pharmaceutical Law (Dz.U. nr 126 poz. 1381 as amended). The subject of the order is the successive supply of the medicinal product ZUCLOPENTHIXOL, described in detail in Appendix No 2A to SWZ (SWZ). The Purchaser requires that the offered medicinal product has been authorized for marketing in the territory of Poland, in accordance with the relevant provisions of the Act of 6 September 2001 on Pharmaceutical Law (Dz.U. Pharmaceutical Law). Pharmaceutical Law (Dz.U. nr 126 poz. 1381 as amended). The subject of the order is successive supply of the medicinal product ZUCLOPENTHIXOL ACETATE , described in detail in Appendix No 2A to SWZ. The Ordering Party requires that the offered medicinal product has been authorized for marketing in the territory of Poland, in accordance with the provisions of the Act of 6 September 2001 on Pharmaceutical Law (Dz. Pharmaceutical Law (Dz.U. nr 126 poz. 1381 as amended).

Opportunity closing date
01 June 2022
Value of contract
to be confirmed

About the buyer

Address
Wojewódzki Szpital Specjalistyczny w Legnicy 59-220 Legnica, ul.Iwaszkiewicza 5 Legnica 59-220 Poland
Contact
zam.publiczne@szpital.legnica.pl

The deadline to apply for this opportunity has passed.
Visit the opportunities page to find another.

Is there anything wrong with this page?